- Investing Ideas
- /
- Hong Kong Pharmaceuticals & Biotech Healthy high growth potential
Hong Kong Pharmaceuticals & Biotech Healthy high growth potential
Results
9
Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.
9 companies
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$116.9b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$511.50
7D
2.2%
1Y
173.5%
Ascentage Pharma Group International
Market Cap: HK$27.9b
A clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.
6855
HK$76.15
7D
-3.5%
1Y
112.4%
RemeGen
Market Cap: HK$61.6b
A biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States.
9995
HK$106.20
7D
4.7%
1Y
810.8%
Akeso
Market Cap: HK$118.8b
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.
9926
HK$129.00
7D
-3.4%
1Y
78.7%
WuXi XDC Cayman
Market Cap: HK$86.6b
An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.
2268
HK$70.55
7D
8.0%
1Y
260.3%
Cutia Therapeutics
Market Cap: HK$3.4b
An investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong.
2487
HK$9.69
7D
-11.9%
1Y
-31.3%
Innovent Biologics
Market Cap: HK$165.3b
A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally.
1801
HK$96.50
7D
-3.1%
1Y
120.3%
Everest Medicines
Market Cap: HK$20.8b
A biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets.
1952
HK$58.75
7D
-2.4%
1Y
161.7%
InnoCare Pharma
Market Cap: HK$32.6b
A biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China.
9969
HK$16.53
7D
-4.8%
1Y
185.0%